EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$70.22
−0.69%Year over year
Reported trailing growth
- Revenue
- +9.1%
- EBITDA
- +22.1%
- EBIT
- +25.4%
- EPS
- +40.8%
- Free cash flow
- +54.8%
- Operating cash flow
- +48.3%
Forward estimates
Based on analyst estimates
- Revenue
- +10.9%
- EBITDA
- +18.4%
- EPS
- +10.9%
Three-year CAGR
- Revenue
- +12.9%
- EBITDA
- +53.4%
- EBIT
- +63.0%
- Net income
- +62.5%
- EPS
- +71.6%
- Free cash flow
- +55.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Oct 1, 2026